Sarepta Therapeutics (SRPT) | Stock Overview & Key Data
Sarepta Therapeutics Performance Comparison
Stock Range
Today's Range
Low: $18.52
High: $20.12
on August 21, 2025
52 Week Range
Low: $10.42
High: $144.22
on July 24, 2025
on August 22, 2024
All-Time High: $181.83 on December 21, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$2.1B
EPS
-0.68
P/E Ratio (TTM)
19.98
Forward P/E
1.83
P/B Ratio
1.51
PEG Ratio
0.01
Div. Yield
N/A
ROE
-4.76%
Beta
0.455
Debt to Equity
100.51
Financial Highlights
Profitability
Gross Margin
75.04%
Operating Margin
18.91%
Profit Margin
-2.34%
Returns and Earnings
Return on Assets (TTM)
-0.02%
Return on Equity (TTM)
-4.76%
EBITDA
$324.7M
Net Income (TTM)
$-58.0M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$25.61
Quarterly Revenue Growth (YoY)
68.40%
Quarterly Earnings Growth (YoY)
2,947.90%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Sarepta Therapeutics SRPT | 2.05B Mid-cap | -1.18% | 50.60% | -49.91% | -81.13% | -83.83% | -85.73% | -82.07% | -86.40% |
| Vertex VRTX | 100.19B Large-cap | 1.83% | -13.31% | -8.70% | -17.92% | -2.05% | -17.41% | 41.10% | 47.23% |
| Regeneron REGN | 62.88B Large-cap | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% | -50.12% | 0.33% | -0.74% |
| BridgeBio Pharma BBIO | 9.39B Mid-cap | -1.86% | 9.43% | 52.95% | 36.31% | 78.12% | 98.46% | 379.29% | 69.75% |
| Madrigal MDGL | 8.46B Mid-cap | 9.62% | 23.01% | 46.84% | 21.07% | 29.74% | 61.07% | 481.06% | 281.74% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
Ownership & Short Interest
Insider Ownership
4.46%
Institutional Ownership
87.07%
Shares Short
21M
Short Ratio
1.14
Short % of Shares Outstanding
25.14%
Average 10-Day Volume
10M
Average 90-Day Volume
18M
Sarepta Therapeutics Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Sarepta Therapeutics would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SRPT's 52-week high and low?
- In the last 52 weeks, Sarepta Therapeutics reached a high of $144.22 (on August 22, 2024) and a low of $10.42 (on July 24, 2025).
- What is the market cap and P/E ratio for SRPT?
- Curious about Sarepta Therapeutics's size and valuation? Its market capitalization stands at 2.05B. When it comes to valuation, the P/E ratio (trailing twelve months) is 19.98, and the forward P/E (looking ahead) is 1.83.
- Does SRPT pay dividends? If so, what's the yield?
- As for dividends, Sarepta Therapeutics isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Sarepta Therapeutics's main competitors or similar companies to consider before investing?
When looking at Sarepta Therapeutics, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.19B Healthcare Biotechnology -17.41% 41.10% Regeneron
REGN62.88B Healthcare Biotechnology -50.12% 0.33% BridgeBio Pharma
BBIO9.39B Healthcare Biotechnology 98.46% 379.29% Madrigal
MDGL8.46B Healthcare Biotechnology 61.07% 481.06% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Sarepta Therapeutics Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Sarepta Therapeutics's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -4.76%, the Debt to Equity ratio from the most recent quarter is 100.51, and its Gross Profit Margin stands at 75.04%.
- What is the recent revenue and earnings growth for SRPT?
- Looking at Sarepta Therapeutics's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 68.40%, and quarterly earnings saw a YoY growth of 2,947.90%.
- How much of SRPT stock is held by insiders and institutions?
- Wondering who owns Sarepta Therapeutics stock? Company insiders (like executives and directors) hold about 4.46% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 87.07%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.